Comparative Pharmacology
Head-to-head clinical analysis: FABRAZYME versus MYOZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABRAZYME versus MYOZYME.
FABRAZYME vs MYOZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fabrazyme (agalsidase beta) is a recombinant human alpha-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal alpha-galactosyl residues, thereby reducing accumulation of these substrates in tissues.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA) that hydrolyzes glycogen to glucose in lysosomes. It replaces deficient GAA enzyme activity in patients with Pompe disease.
1 mg/kg intravenously every 2 weeks infused over 4-6 hours.
20 mg/kg IV every 2 weeks.
None Documented
None Documented
Terminal elimination half-life ranges from 80 to 120 minutes (1.3-2 hours) in adults, which supports a bi-weekly intravenous dosing regimen.
The terminal elimination half-life of alglucosidase alfa is approximately 2.3 hours at steady state. This short half-life necessitates weekly intravenous infusions to maintain therapeutic enzyme levels in target tissues.
Primarily eliminated via renal pathways; 55-65% of the administered dose is recovered in urine as unchanged drug, with less than 5% recovered in feces.
Renal elimination is the primary route of clearance for alglucosidase alfa. Following intravenous administration, the drug is cleared via catabolism into small peptides and amino acids, which are then excreted renally. Less than 5% of the administered dose is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy